2018 will be the year gene therapies come into their own. After decades of unfulfilled potential, this space is gaining tangible momentum, particularly in addressing the significant unmet need in a range of rare diseases.
Gene Therapy for Rare Disorders 2018 will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market.
Incorporating insights from Spark, Bluebird Bio, Pfizer and GSK, this unique conference will delve into the key regulatory, reimbursement, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies.
Join your colleagues to accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.
“I really enjoyed the broad spectrum of topics that the conference covered and the networking opportunities.”
- Samantha Galuska, Sanofi
“I’m looking forward to a meeting bringing minds together and rallying us behind our field’s banner in preparation of what should be a momentous year”
- Adrien Lemoine, Orchard Therapeutics